Get the Stockscreener App
78.71
0.78%
0.61
After Hours:
78.50
-0.21
-0.27%
Edwards Lifesciences Corp stock is traded at $78.71, with a volume of 6.48M.
It is up +0.78% in the last 24 hours and down -8.32% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$78.10
Open:
$78.705
24h Volume:
6.48M
Relative Volume:
1.81
Market Cap:
$45.68B
Revenue:
$5.88B
Net Income/Loss:
$1.34B
P/E Ratio:
33.51
EPS:
2.3489
Net Cash Flow:
$799.60M
1W Performance:
-3.26%
1M Performance:
-8.32%
6M Performance:
+0.13%
1Y Performance:
+10.87%
1-Day Range:
$77.44
$78.89
1-Week Range:
$77.44
$83.77
52-Week Range:
$65.94
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
78.71 | 45.32B | 5.88B | 1.34B | 799.60M | 2.3489 |
|
ABT
Abbott Laboratories
|
110.83 | 189.68B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
358.29 | 138.60B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
102.90 | 131.98B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
76.27 | 115.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-03-25 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Stock Analysis: Is Edwards Lifesciences Corporation a stock for growth or value investors2025 EndofYear Setup & High Accuracy Investment Signals - baoquankhu1.vn
Edwards Lifesciences Nears SAPIEN M3 Decision As Big Money Moves - simplywall.st
FTC Victory in Edwards Lifesciences Merger: 4 Key Takeaways for Life Sciences Deals - JD Supra
Edwards Lifesciences advances smart surgery monitoring with completed SMART TRENDS study - MSN
Seal The Valve, But Not The Deal: Court Blocks Edwards Lifesciences' Pre Commercial Merger - marketscreener.com
Edwards Lifesciences' Q4 Earnings on Deck: Here's What to Expect - Yahoo Finance
4 Lessons From FTC's Successful Bid To Block Edwards Deal - Law360
Edwards Lifesciences to Host Earnings Conference Call on February 10, 2026 - Barchart.com
Edwards Lifesciences completes key study on SAPIEN XT THV - MSN
Edwards Lifesciences Corporation (EW): A Bull Case Theory - Finviz
Edwards Lifesciences to Present at the TD Cowen 46th Annual Health Care Conference - BioSpace
Should Weakness in Edwards Lifesciences Corporation's (NYSE:EW) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - Yahoo Finance
Edwards Lifesciences CFO Scott Ullem to speak at TD Cowen health care event - stocktitan.net
Analyst Upgrades Signal Renewed Growth Cycle for Edwards Lifesciences Corporation (EW) - Finviz
Renewed Growth Cycle Drives a Favorable Sentiment Towards Edwards Lifesciences (EW) - Finviz
J. Safra Sarasin Holding AG Buys New Shares in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards’ request for broader TAVR Medicare coverage gets pushback - MedTech Dive
Bank of New York Mellon Corp Increases Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
ACQUISITIONS & MERGERS—D.D.C.: Opinion granting FTC win in Edwards Lifesciences case details reasoning - VitalLaw.com
Judge: Edwards/Jenavalve would create “total monopoly” - Global Competition Review
Sector Gamma AS Acquires 30,980 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Sells 25,276 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Profit Review: Will Edwards Lifesciences Corporation outperform its industry peersMarket Rally & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Heart Valve Deal Was Blocked Over Innovation Concerns - Law360
Edwards Lifesciences (NYSE:EW) Issues FY 2026 Earnings Guidance - MarketBeat
What to expect from Edwards Lifesciences' Q4 2025 earnings report - MSN
Universal Beteiligungs und Servicegesellschaft mbH Raises Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Allstate Corp Buys Shares of 21,090 Edwards Lifesciences Corporation $EW - MarketBeat
VIX Spike: Can GBFH sustain earnings growthJuly 2025 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn
Aug Action: Is Edwards Lifesciences Corporation showing insider buyingQuarterly Investment Review & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Edwards Lifesciences (EW) Receives New Analyst Target Price from Piper Sandler | EW Stock News - GuruFocus
Stifel raises Edwards Lifesciences stock price target to $110 on TAVR growth - Investing.com Canada
Edwards Lifesciences Corp. Still Trying To Regain Footing - AOL.com
Does Edwards Lifesciences (EW) Have Strong Double-Digit Earnings Potential? - Insider Monkey
What Is Edwards Lifesciences Corporation's (NYSE:EW) Share Price Doing? - Yahoo Finance
Edwards Lifesciences Corporation (NYSE:EW) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Short Interest Update - MarketBeat
IBD Rating Upgrades: Edwards Lifesciences Flashes Improved Technical Strength - Investor's Business Daily
Edwards’ Heart Valve Clips Targeted by Cardiovalve Patent Suit - Bloomberg Law News
Market Review: Whats the outlook for Edwards Lifesciences Corporations sectorPortfolio Risk Summary & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Boston Scientific Acquires Penumbra In $14.5 Billion Bet To Dominate Thrombectomy - Benzinga
Edwards Lifesciences (EW) Valuation Check As Recent Share Momentum Meets Premium P/E Pricing - Yahoo Finance
Risk Report: Does Edwards Lifesciences Corporation align with a passive investing strategy2025 Top Gainers & Expert Curated Trade Ideas - baoquankhu1.vn
JPM26: Edwards Lifesciences targets 10% growth in 2026 - Yahoo Finance
Is it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now? - Yahoo Finance
Palmetto Grain Brokerage - Palmetto Grain Brokerage
What to Expect From Edwards Lifesciences' Q4 2025 Earnings Report - Yahoo Finance
Nordea Investment Management AB Sells 110,464 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Spire Wealth Management Decreases Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
UBS Revises Edwards Lifesciences (EW) Price Target and Maintains Neutral Rating | EW Stock News - GuruFocus
Barclays Raises Price Target for Edwards Lifesciences (EW) to $1 - GuruFocus
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
2.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):